Neonatal thrombocytosis following G-CSF treatment
نویسندگان
چکیده
منابع مشابه
Morphological features following G-CSF treatment.
RhG-CSF is widely used in hematology and oncology for the amelioration of chemotherapy induced neutropenia, for the restoration of neutrophil production after bone marrow transplantation, and for other conditions such as myelodysplastic syndromes, aplastic anemia and severe chronic neutropenia. Moreover, RhG-CSF is able to bring about a lot of functional and phenotype modifications in the induc...
متن کاملMaternal narcotic abuse and neonatal thrombocytosis.
responsiveness as severe as that of the asthmatics. Moreover, with very few positive airway responders in a small study group it would be difficult to show a significant difference statistically, even if such a difference had existed. Additionally, without a reference population, they cannot say whether their findings were normal or abnormal. In our own study of a cohort of low birthweight chil...
متن کاملGM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
BACKGROUND G-CSF and GM-CSF have both been shown to decrease the time to hematopoietic recovery when administered after autologous BM or peripheral stem cell re-infusion. However, few studies have compared G-CSF and GM-CSF to determine which is the preferred myeloid growth factor. METHODS This study compares a prospectively accrued cohort of 22 patients receiving GM-CSF with a historical coho...
متن کاملThrombocytosis following thrombocytopenia in man.
Introduction An elevation in the circulating platelet count has been observed in a variety of physiological and pathological conditions. However, the rise in platelets varies widely in timing and duration. The myeloproliferative diseases are frequently accompa-nied by a persistent increase in the platelet count which may be of considerable magnitude. Such stresses as exercise are accompanied by...
متن کاملG-CSF and GM-CSF in Neutropenia.
G-CSF and GM-CSF are used widely to promote the production of granulocytes or APCs. The U.S. Food and Drug Administration approved G-CSF (filgrastim) for the treatment of congenital and acquired neutropenias and for mobilization of peripheral hematopoietic progenitor cells for stem cell transplantation. A polyethylene glycol-modified form of G-CSF is approved for the treatment of neutropenias. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Toxicology
سال: 2007
ISSN: 1556-3650,1556-9519
DOI: 10.1080/15563650701638883